Palisade Bio Strengthens Phase 2 Case for PALI-2108 with New IBD Data

  • Palisade Bio presented five posters at ACG 2026, with two winning Presidential Poster Awards
  • Phase 1b data showed early clinical activity in UC and fibrostenotic Crohn’s disease
  • Microbiome and transcriptomic analyses support targeted delivery and potential precision medicine approach
  • Phase 2 studies (ASCENTRA-UC and Crohn’s disease program) are ongoing

Palisade Bio’s data reinforces the rationale for its gut-targeted PDE4 inhibitor in IBD, a space dominated by biologics and JAK inhibitors. The microbiome-activated delivery platform could offer a differentiated approach if Phase 2 results hold. Success hinges on demonstrating superior efficacy and tolerability in head-to-head comparisons.

Clinical Validation
Whether Phase 2 data will confirm early signals of efficacy in larger, controlled studies
Precision Medicine
The pace at which transcriptomic signatures can enable patient stratification
Competitive Positioning
How sustained systemic exposure compares to existing PDE4 inhibitors like apremilast